Start with mRNA.
Produce the RNA using an established in vitro transcription workflow.
A programmable chemical control layer for mRNA. Built after synthesis. Designed around the performance you need.
Conventional mRNA production limits the chemistry you can use. Amptiv adds chemical modifications after synthesis, opening new ways to engineer how an mRNA performs.
We’re developing stable and reversible modifications to tune mRNA for the demands of different applications.
Explore how added chemistry changes translation. Our goal is to match expression to the application, from a defined pulse to sustained protein production.
Stable and reversible chemistries create different routes to influence when an mRNA is translated and how long its activity lasts.
Chemical modification of mRNA offers a route to improve molecular stability. We evaluate integrity alongside functional performance.
Chemical modifications offer the potential to tune how the immune system senses and responds to mRNA, helping align immune responses with therapeutic goals.
Our chemistry starts where conventional design and synthesis stop, adding a new dimension to the RNA development workflow.
Produce the RNA using an established in vitro transcription workflow.
Introduce chemical groups after synthesis through Amptiv’s modification technology.
Evaluate molecular integrity and functional performance in the context of the intended application.
Amptiv is now offering early access to TailX™, a new mRNA poly(A) tail modification kit. Evaluate longer-lasting expression in your own systems.
Amptiv chemically engineers mRNA after synthesis to tune expression, durability, stability, and immune response. We’re building a programmable control layer to help therapeutic developers match mRNA performance to the demands of each medicine.
Partner with Amptiv to engineer the expression, durability, and biological response your mRNA therapeutic needs.